257 related articles for article (PubMed ID: 36942414)
1. T-cell exhaustion in CAR-T-cell therapy and strategies to overcome it.
Yin X; He L; Guo Z
Immunology; 2023 Aug; 169(4):400-411. PubMed ID: 36942414
[TBL] [Abstract][Full Text] [Related]
2. Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion.
Lamarche C; Ward-Hartstonge K; Mi T; Lin DTS; Huang Q; Brown A; Edwards K; Novakovsky GE; Qi CN; Kobor MS; Zebley CC; Weber EW; Mackall CL; Levings MK
Proc Natl Acad Sci U S A; 2023 Apr; 120(14):e2219086120. PubMed ID: 36972454
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
Shen C; Zhang Z; Zhang Y
Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182
[TBL] [Abstract][Full Text] [Related]
4. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours.
Mao R; Hussein MS; He Y
Expert Rev Mol Med; 2022 Jan; 24():e7. PubMed ID: 35086597
[TBL] [Abstract][Full Text] [Related]
6. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
7. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
Gumber D; Wang LD
EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
[TBL] [Abstract][Full Text] [Related]
8. Applications of single-cell omics for chimeric antigen receptor T cell therapy.
Ghaffari S; Saleh M; Akbari B; Ramezani F; Mirzaei HR
Immunology; 2024 Mar; 171(3):339-364. PubMed ID: 38009707
[TBL] [Abstract][Full Text] [Related]
9. Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data.
Sahoo P; Yang X; Abler D; Maestrini D; Adhikarla V; Frankhouser D; Cho H; Machuca V; Wang D; Barish M; Gutova M; Branciamore S; Brown CE; Rockne RC
J R Soc Interface; 2020 Jan; 17(162):20190734. PubMed ID: 31937234
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.
Choi BD; Maus MV; June CH; Sampson JH
Clin Cancer Res; 2019 Apr; 25(7):2042-2048. PubMed ID: 30446589
[TBL] [Abstract][Full Text] [Related]
11. Exhaustion of CAR T cells: potential causes and solutions.
Kouro T; Himuro H; Sasada T
J Transl Med; 2022 May; 20(1):239. PubMed ID: 35606821
[TBL] [Abstract][Full Text] [Related]
12.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
13. Engineering chimeric antigen receptor T cells for solid tumour therapy.
Liu L; Qu Y; Cheng L; Yoon CW; He P; Monther A; Guo T; Chittle S; Wang Y
Clin Transl Med; 2022 Dec; 12(12):e1141. PubMed ID: 36495108
[TBL] [Abstract][Full Text] [Related]
14. Strategies to overcome the side effects of chimeric antigen receptor T cell therapy.
Mirzaee Godarzee M; Mahmud Hussen B; Razmara E; Hakak-Zargar B; Mohajerani F; Dabiri H; Fatih Rasul M; Ghazimoradi MH; Babashah S; Sadeghizadeh M
Ann N Y Acad Sci; 2022 Apr; 1510(1):18-35. PubMed ID: 34982476
[TBL] [Abstract][Full Text] [Related]
15. Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations.
Brookens SK; Posey AD
Cancer J; 2023 Jan-Feb 01; 29(1):28-33. PubMed ID: 36693155
[TBL] [Abstract][Full Text] [Related]
16. Decoding and overcoming TÂ cell exhaustion: Epigenetic and transcriptional dynamics in CAR-T cells against solid tumors.
Ahn T; Bae EA; Seo H
Mol Ther; 2024 Jun; 32(6):1617-1627. PubMed ID: 38582965
[TBL] [Abstract][Full Text] [Related]
17. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
18. [Development of next-generation chimeric antigen receptor-engineered T-cell therapy].
Kagoya Y
Rinsho Ketsueki; 2022; 63(9):1290-1297. PubMed ID: 36198555
[TBL] [Abstract][Full Text] [Related]
19. Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies.
Abbott RC; Cross RS; Jenkins MR
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31947597
[TBL] [Abstract][Full Text] [Related]
20. Chimeric Antigen Receptor (CAR) T-cell Therapy: A New Genetically Engineered Method of Immunotherapy for Cancer.
Singh AK; Malviya R; Singh A; Sundram S; Mishra S
Curr Cancer Drug Targets; 2023; 23(3):199-210. PubMed ID: 36173082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
